BMY vs. ZTS, PFE, ABBV, MRK, GSK, VRTX, REGN, SNY, TAK, and ABT
Should you be buying Bristol-Myers Squibb stock or one of its competitors? The main competitors of Bristol-Myers Squibb include Zoetis (ZTS), Pfizer (PFE), AbbVie (ABBV), Merck & Co., Inc. (MRK), GSK (GSK), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Sanofi (SNY), Takeda Pharmaceutical (TAK), and Abbott Laboratories (ABT). These companies are all part of the "pharmaceutical preparations" industry.
Zoetis (NYSE:ZTS) and Bristol-Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, community ranking, media sentiment, risk, profitability and institutional ownership.
Zoetis has a net margin of 27.38% compared to Zoetis' net margin of -13.50%. Bristol-Myers Squibb's return on equity of 50.34% beat Zoetis' return on equity.
Zoetis pays an annual dividend of $1.73 per share and has a dividend yield of 1.0%. Bristol-Myers Squibb pays an annual dividend of $2.40 per share and has a dividend yield of 5.5%. Zoetis pays out 33.3% of its earnings in the form of a dividend. Bristol-Myers Squibb pays out -77.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has raised its dividend for 13 consecutive years and Bristol-Myers Squibb has raised its dividend for 16 consecutive years. Bristol-Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
92.8% of Zoetis shares are held by institutional investors. Comparatively, 76.4% of Bristol-Myers Squibb shares are held by institutional investors. 0.2% of Zoetis shares are held by insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Zoetis has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500.
Bristol-Myers Squibb received 180 more outperform votes than Zoetis when rated by MarketBeat users. However, 77.82% of users gave Zoetis an outperform vote while only 66.87% of users gave Bristol-Myers Squibb an outperform vote.
Bristol-Myers Squibb has higher revenue and earnings than Zoetis. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.
In the previous week, Zoetis had 22 more articles in the media than Bristol-Myers Squibb. MarketBeat recorded 52 mentions for Zoetis and 30 mentions for Bristol-Myers Squibb. Zoetis' average media sentiment score of 0.62 beat Bristol-Myers Squibb's score of 0.46 indicating that Bristol-Myers Squibb is being referred to more favorably in the news media.
Zoetis currently has a consensus price target of $211.75, suggesting a potential upside of 28.40%. Bristol-Myers Squibb has a consensus price target of $60.00, suggesting a potential upside of 37.39%. Given Zoetis' higher possible upside, analysts plainly believe Bristol-Myers Squibb is more favorable than Zoetis.
Summary
Zoetis beats Bristol-Myers Squibb on 13 of the 21 factors compared between the two stocks.
Get Bristol-Myers Squibb News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bristol-Myers Squibb Competitors List
Related Companies and Tools
